Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. - Wikidata - awgldk - TriplyDB

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.

http://www.wikidata.org/entity/Q38334787

about

Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis Infection Risk and Safety of Corticosteroid Use.Cyclophosphamide in dermatology.Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?CMV disease complicating induction immunosuppressive treatment for ANCA-associated vasculitis.Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression.Thoracic manifestation of Wegener's granulomatosis: Computed tomography findings and analysis of misdiagnosis.Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.antineutrophil cytoplasmic antibody-associated vasculitis in pregnancy: a systematic review on maternal, pregnancy and fetal outcomes Therapeutic Management of Pediatric Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

P2860

Q26752836-DE3D67A5-BF0E-4229-AB55-3FE9C64F9C78 Q26753833-64F48804-4586-46EB-87D7-876134A5CEA9 Q36574609-8679BED0-2501-4DD0-A7D2-6E2A4BD38F97 Q38710150-A129B6F2-C63A-4A80-B9A0-FE60689A72D0 Q38794907-AFD955ED-F09E-44E2-8562-791B3C50FF5D Q40780383-777DE421-598E-463F-847D-1F774219A517 Q48305722-BA7B0D85-9259-439F-9CCB-A9B5049F16C0 Q55023202-AA273C26-8503-433B-8832-7F45D0268948 Q55440952-E8889CD9-D66D-44C0-8CB7-08DBE3846E88 Q57053858-568E208D-C389-4248-B907-A6A3209AEB2D Q59160663-E1E748EF-3F2E-40A8-8C32-83B5857A5534

P2860

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.

http://www.wikidata.org/entity/Q38334787

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.

@en

type

label

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.

@en

prefLabel

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.

@en

P1433

Q38334787-22E5D4E2-AF01-4691-9206-92663089D511

P1476

Q38334787-DB729692-E18B-4503-B5CA-96846889AB49

P2093

Q38334787-B6B2C3F4-3EC8-4EA2-A7BD-259C8CC8A779

P2860

Q38334787-06318D31-D8CA-4F3D-938F-F621EB87A3BE

Q38334787-0AA5C93B-3ECF-402E-A84C-D5F7BD228234

Q38334787-117C3F32-8332-417C-92E3-D7EFE936472D

Q38334787-13506301-2AF9-4F85-B152-05BA5512FAC5

Q38334787-18E82604-5F30-4838-AF9E-945621875E1F

Q38334787-18FBF11E-5932-4DB1-BA16-7CC4270BA9FE

Q38334787-1DFC4B1D-B516-4BE0-96A8-03D35A4E37DB

Q38334787-2C4E86BD-4845-4294-985A-9E4C1D09BD37

Q38334787-33F246D2-23ED-404B-AB8D-E0DA880E5BA3

Q38334787-3C44FEF9-527E-4C37-8432-519FA4662DB7

P304

Q38334787-2252115B-4738-4B8A-A013-F260F07CC6E6

P31

Q38334787-E25C33D2-5B5E-4804-9B24-B2785172CCD2

P356

Q38334787-9993329D-8DC2-4DD9-B3A1-96B19E44C8DC

P433

Q38334787-9AE80BCC-2155-41E2-8F23-C83DBF2BFE33

P478

Q38334787-1E36CC6E-8C3C-47AB-8AE9-3F72DA7E4E02

P50

Q38334787-4AAA4FC2-27AA-47A3-A8CE-1C94FF0417A4

Q38334787-C597EB57-CDB0-4EEB-9401-A9416790EF39

P577

Q38334787-592356CF-3839-4BD0-B3CB-D4F35FDBF3A3

P5875

Q38334787-2B4F5AC1-64A5-4556-93DA-406365882CF3

P698

Q38334787-F8A1053A-15CB-4ADB-996F-D238683C44E0

P356

P1433

European Journal of Clinical Investigation

P1476

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.

@en

P2093

David R W Jayne

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis

Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis.

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.

Etanercept plus standard therapy for Wegener's granulomatosis.

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.

Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis.

P304

346-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ECI.12410

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Kronbichler

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271458905

http://www.w3.org/2001/XMLSchema#string

P698

25627555

http://www.w3.org/2001/XMLSchema#string